Funded Tech Companies
REGENXBIO
REGENXBIO, operating out of Rockville, received equity investments from private investors, Jennison Associates and Deerfield Capital.
Company Overview
Company Name
REGENXBIO
Company Status
Publicly-held
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
9600 Blackwell Rd. 210
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Not Recorded
Company Background Information
Overview
REGENXBIO (NASDAQ: RGNX) is leveraging our proprietary NAV Technology to advance the development of life-changing adeno-associated viral (AAV) gene therapy treatments for lysosomal storage disorders and ocular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
9/17/2015
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ken Mills
Chief Financial Officer
Vit Vasista
Chief Medical Officer
Stephen Yoo
Chief Scientific Officer
Olivier Danos
Chief Technical Officer
Curran Simpson
VP - General Counsel
Patrick Christmas
VP - Human Resources
Shiva Fritsch
VP - Operations
Ram Palanki
Company Investors
- Jennison Associates
- Deerfield Capital
- Brookside Capital
- Vivo Capital (Edgar Engelman)
- Venrock (Bong Koh)
- Foresite Capital
- F-Prime Capital
- Sectoral Asset Management
- QVT Fund
- Cormorant Asset Management
- Perceptive Advisors
- Janus Capital
- Venrock (Camille Samuels)
Browse more funded tech companies:
Regentis Biomaterials | RegGenome
Share this article
About Our Venture Capital Database
Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs